PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
Similarly, enzalutamide monotherapy was associated with superior 5-year metastasis-free survival rates, compared to leuprolide monotherapy (80% versus 71%; HR 0.63, p = 0.005). 2 However, the ...
After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...
A drug called Xtandi ( enzalutamide) is poised to change the standard of care ... Most recently, the phase 3 EMBARK trial looked at the best treatment for high-risk prostate cancer that had returned ...
Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...
Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...
LV= has today (27 January) fully launched its ‘Platform Services’ option for advisers, in partnership with technology provider Embark. The announcement follows a 12-month controlled launch ...
Key Pfizer presentations at ASCO GU include the detailed overall survival (OS) results from the Phase 3 TALAPRO-2 trial with TALZENNA ® (talazoparib) plus XTANDI ® (enzalutamide) in patients ...
To Kill a Mockingbird will be touring the nation later this year. Directed by Bartlett Sher (The King and I), Aaron Sorkin’s adaptation of Harper Lee’s seminal text was seen in the West End in 2022, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results